Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial - Goldschmidt, Hartmut; Mai, Elias K.; Bertsch, Uta; Fenk, Roland; Nievergall, Eva; Tichy, Diana; Besemer, Britta; Dürig, Jan; Schroers, Roland; von Metzler, Ivana; Hänel, Mathias; Mann, Christoph; et al. (The lancet. Haematology, 2022)
Gesehen am 08.11.2022